View Financial Health4basebio 配当と自社株買い配当金 基準チェック /064basebio配当金を支払った記録がありません。主要情報n/a配当利回り-0.04%バイバック利回り総株主利回り-0.04%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • 4h4basebio PLC, Annual General Meeting, Jun 30, 20264basebio PLC, Annual General Meeting, Jun 30, 2026. Location: the offices of 4basebio plc, United KingdomReported Earnings • 10hFull year 2025 earnings released: UK£1.09 loss per share (vs UK£0.94 loss in FY 2024)Full year 2025 results: UK£1.09 loss per share (further deteriorated from UK£0.94 loss in FY 2024). Net loss: UK£16.9m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • May 15+ 1 more update4basebio PLC Appoints Richard Bungay as Chief Financial Officer, with Effect from July 20264basebio PLC announced appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period. Richard is an accomplished leader with over 30 years’ senior finance and strategic experience within the pharmaceutical and biotechnology sector, leading both public and private companies from research through all clinical phases, regulatory approval and commercialisation. He joins 4basebio from Sitala Bio Limited, a UK-based private biotech where he helped lead a strategic repositioning of the business, working closely with the CEO and board to raise a signficant Series A round and execute an in-licencing deal with Fosun Pharma for up to $670 million. Richard’s prior roles include CEO and CFO at Diurnal Group plc, where he led its acquisition by Neurocrine Biosciences Inc. in 2022 at a 147% one-day premium, CEO and CFO at Mereo Biopharma Group plc, where he helped in-license a portfolio from Novartis and subsequently completed its AIM IPO, and CFO at Verona Pharma (then listed on the London Stock Exchange, now a subsidiary of Merck & Co) where he helped recapitalise the company. Earlier in his career Richard was the Director of Corporate Communications and Strategic Planning at Celltech Group plc, a London-listed FTSE-100/250 company where he helped execute its acquisition by UCB for £1.5bn. Richard is currently a Non-executive Director of Chroma Therapeutics Ltd. He qualified as a Chartered Accountant with Deloitte and has a First Class degree in Chemistry from Nottingham University.お知らせ • May 124basebio PLC Launches Enzymatic ssDNA Platform4basebio PLC announced the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines. Built on a proprietary enzymatic manufacturing process, the platform provides biopharma with high-purity, long-form ends protected ssDNA templates, designed to overcome critical manufacturing and performance bottlenecks associated with traditional chemical synthesis in CRISPR-based gene editing, enabling large-scale, clinically viable therapeutics. With the growth of gene editing and with a particular need for complex "knock-in" applications, the demand for longer, purer and safer DNA templates has increased exponentially. 4basebio’s ssDNA offering enables the production of constructs up to 10,000 nucleotides with protected ends, ensuring stability, reduced immunogenicity and a cleaner path to clinical manufacturing. The technical advantages of the platform will be showcased at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston, MA. Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, will deliver a presentation titled "An enzymatic ssDNA platform addresses manufacturing and performance bottlenecks in non-viral CRISPR gene editing" on 14 May at 9:00 AM EDT. At ASGCT, I look forward to presenting data that demonstrates how our long-form ssDNA constructs significantly enhance Homology Directed Repair (HDR) gene editing efficiency while maintaining superior cell viability in sensitive primary cell types. This technology is the bridge between discovery-phase editing and large-scale clinical success. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.New Risk • May 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£71.2m (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£71.2m market cap, or US$96.6m).New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m).New Risk • Mar 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£74.0m (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£74.0m market cap, or US$99.0m).お知らせ • Mar 034basebio PLC Promotes Christine Wolosin to Chief Commercial Officer4basebio PLC announced the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice President, Business Development, will lead the Company's global commercial strategy, business development initiatives, and customer engagement as the Company scales its innovative synthetic DNA platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine markets.Christine’s promotion follows the appointment of Dr Amy Walker as Chief Executive Officer, replacing Dr Heikki Lanckriet. Christine will work closely with Amy to execute 4basebio’s accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers seek alternatives to plasmid DNA. Christine brings more than 25 years of experience in the life sciences industry, with a proven track record of building and scaling go-to-market capabilities in the cell and gene therapy space. Prior to joining 4basebio, she served as Vice President of Business Development at Emmes, where she led the buildout of the North America commercial organisation to support growth in biopharma innovator trials and later-phase studies. She established scalable, globally aligned commercial processes and advanced Emmes’ strategic positioning within the biopharma sector. Christine has also held senior global commercial leadership roles at leading life sciences organizations including TriLink BioTechnologies and Thermo Fisher Scientific, where she led the go-to-market launches for a number of advanced therapy offerings, including Thermo Fisher Scientific’s viral vector manufacturing expansion at its flagship Plainville, Massachusetts facility.お知らせ • Feb 104basebio PLC Announces CEO Changes4basebio PLC announced that Dr Amy Walker has been appointed as Chief Executive Officer, succeeding Dr Heikki Lanckriet, Founder of the Company. After six years in the role, Heikki has stepped down as CEO in order to lead a newly formed entity which will be focussed on advancing the Hermes nanoparticle platform into the clinic. The Board and Executive Leadership team determined that Amy, with her deep knowledge of the company and commercially-focussed skillset and experience, is the right candidate to succeed Heikki as the Company prepares for accelerated commercial growth. Heikki will remain on the Board and will also continue to support the Company’s scientific and technical leadership. David Roth will join Heikki in the newly formed entity and will step down as Chief Financial Officer and as a Director, following an orderly handover period. Amy has been with the Company for more than five years most recently serving as Chief Operating Officer. She has played a key role in scaling 4basebio’s GMP manufacturing capabilities, strengthening direct engagement with top-tier biopharma customers and supporting the Company’s growth operationally and strategically. As Chief Executive Officer, Amy will lead an accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers increasingly seek alternatives to plasmid DNA, and building on the Company’s recent GMP milestone to support clinical programmes in cell and gene therapy and vaccine development. Since the Company’s formation in 2020, Heikki has been responsible for leading 4basebio as it scaled its synthetic DNA technology from concept to clinic, built a global customer base and stewarded 4basebio in building its high-quality investor base.Reported Earnings • Oct 01First half 2025 earnings released: UK£0.50 loss per share (vs UK£0.45 loss in 1H 2024)First half 2025 results: UK£0.50 loss per share (further deteriorated from UK£0.45 loss in 1H 2024). Net loss: UK£7.80m (loss widened 36% from 1H 2024). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.New Risk • Jun 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£18m net loss next year). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£933k revenue, or US$1.3m).Reported Earnings • Jun 02Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: UK£0.94 loss per share (further deteriorated from UK£0.62 loss in FY 2023). Net loss: UK£12.3m (loss widened 61% from FY 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 5.0%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.New Risk • May 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 41% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.2m). Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Revenue is less than US$1m (UK£596k revenue, or US$803k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£15m net loss next year).お知らせ • May 284basebio PLC, Annual General Meeting, Jun 27, 20254basebio PLC, Annual General Meeting, Jun 27, 2025.New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.2m). Revenue is less than US$1m (UK£596k revenue, or US$789k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (UK£12m net loss in 3 years).お知らせ • Apr 024basebio Receives GMP Licence for its UK DNA Manufacturing Facility4basebio PLC announced that it has received Good Manufacturing Practice (GMP) certification from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its UK DNA manufacturing facility. The GMP certification (MIA) granted by the MHRA authorises 4basebio to manufacture and supply both Investigational Medicinal Product (IMP) Drug Substance (Active Pharmaceutical Ingredient; API) and Critical Starting Biological Medicinal materials used in Advanced Therapy Medicinal Products (ATMPs) from its state-of-the-art manufacturing facility in Cambridge. The grant of the GMP certification marks a significant achievement for the Company, proving its ability to produce high-quality, advanced synthetic DNA that meets regulatory standards for clinical applications. The certification both strengthens the Company’s position in the field of advanced therapeutics and progresses the Company towards future product commercialisation and patient care for a range of advanced therapies.お知らせ • Jan 084basebio PLC Appoints Gabe Longoria as Chief Commercial Officer4basebio PLC announced the appointment of Mr. Gabe Longoria as Chief Commercial Officer (“CCO”) of the Company. The appointment follows the completion of the £40 million investment announced on 12 November 2024, which marked a key milestone in the Company’s journey to deliver scalable, high-quality synthetic DNA solutions to the global market, addressing critical needs in the gene therapy and mRNA vaccine sectors. Gabe’s expertise in scaling commercial operations will play a crucial role in ensuring the Company’s synthetic DNA products reach their full market potential and the Company is well-positioned to deliver on its growth and commercialisation goals in 2025 and beyond. Gabe joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations Ltd. (“Astrea”). During his leadership, the company achieved exceptional financial growth, doubling revenues over a three-year period and expanding its market share globally. His strategic approach to scaling operations and fostering key partnerships solidified Astrea’s position as a leader in biopharmaceutical manufacturing solutions. Gabe has over two decades of commercial leadership in the life sciences sector and expertise in driving revenue growth, market expansion, and strategic partnerships for companies.お知らせ • Dec 174basebio PLC Announces Appointment of Alan Malus as Independent Non-Executive Director4basebio PLC announced the appointment of Alan Malus as Independent Non-executive Director of the Company, as of 16 December 2024. Mr. Malus has over 18 years of experience in life sciences and diagnostics, having most recently served as Corporate Executive Vice President and President of the Laboratory Products and Services Segment at Thermo Fisher Scientific. He joined Thermo Fisher in 1998, holding numerous executive positions including President Analytical Technologies Group, President Lab Products Group, and President Customer Chanels Group. Prior to this, Mr. Malus spent nearly 15 years in the automotive industry, working with Ford, Chrysler, and Textron Inc., where he served as Vice President of Finance. Since 2023, Mr. Malus has been a Director at Industrial Physics Inc. He also serves as Director at Azenta Life Sciences. Previously, he served as a Director at PHC Holdings Corporation in Japan (2021 to 2022). Mr. Malus graduated from the University of Michigan in 1981, starting his career as a financial analyst at Ford in 1984 and moving to Chrysler in 1986. Current Directorships: USAJapan; Azenta Inc.; Industrial Physics Inc. Previous Directorships held in the past five years: PHC Holdings Corporation.Recent Insider Transactions • Dec 02Key Executive recently bought UK£158k worth of stockOn the 28th of November, Heikki Lanckriet bought around 12k shares on-market at roughly UK£13.15 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£1.2m. Heikki has been a buyer over the last 12 months, purchasing a net total of UK£158k worth in shares.お知らせ • Nov 134basebio PLC has completed a Follow-on Equity Offering in the amount of £40.000005 million.4basebio PLC has completed a Follow-on Equity Offering in the amount of £40.000005 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,666,667 Price\Range: £15 Transaction Features: Subsequent Direct ListingReported Earnings • Oct 01First half 2024 earnings released: UK£0.45 loss per share (vs UK£0.29 loss in 1H 2023)First half 2024 results: UK£0.45 loss per share (further deteriorated from UK£0.29 loss in 1H 2023). Net loss: UK£5.73m (loss widened 61% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.お知らせ • Aug 094Basebio plc Announces Formation of Strategic Advisory Board and Board Appointment4basebio PLC announced the formation of a Strategic Advisory Board and the appointment of Dr. Amy Walker, the Vice President of Research and Business Development to the Board of Directors of the Company as Chief Operating Officer. Strategic Advisory Board Effective from 1 July 2024, the Company formed a Strategic Advisory Board (“SAB”), with the purpose of offering the Company’s leadership team valuable advice and industry insight spanning technical, operational, commercial and strategic matters as well as supporting the Company in the realisation of its growth goals and objectives. The SAB advisers are engaged for an initial period of 12 months from its formation and will meet with the leadership team periodically. The SAB comprises the following experts: Bertrand Coissac, CEO at Twogene: Mr. Coissac has extensive experience in the life science industry with a focus on cell and gene therapy manufacturing. Before co-founding and leading Twogene, Mr. Coissac was Vice President of Corporate Development at Polyplus which was successfully acquired by Sartorius in July 2023. Lawrence Pitcher, VP at Catalent Pharma Solutions: Mr. Pitcher is currently the Vice President and General Manager, Maryland Gene Therapy Sites at Catalent Pharma Solutions. He brings significant operational and business experience from his current Catalent role and previous roles at Thermo Fisher Scientific where he was most recently the General Manager of the Advance Therapies business. Deborah Barbara, Former Vice President at Maravai Life Sciences: Ms. Barbara has over 30 years of life science industry experience in a variety of strategic business and corporate development roles, most recently as Vice President of Strategy and Corporate Development for Maravai Life Sciences. Prior to joining Maravai, Ms. Barbara was General Manager of Nucleic Acid Therapeutics business for Thermo Fisher Scientific. Appointment of Director: In addition to the above, the Company announces the appointment of Dr. Amy Walker as Chief Operating Officer of the Company. Dr. Walker joined 4basebio in November 2020 and has served as the Vice President of Research and Business Development at the Company. Dr. Walker has a background in molecular biology and gene editing technologies, along with associated nucleic acid nanoparticle delivery platforms. She holds a PhD from UCL Institute of Child Health and was awarded the prestigious Bogue Fellowship, conducting part of her doctoral studies at both University of British Colombia and McGill University, Montreal. Dr. Walker has many years scientific and commercial experience in life sciences, has published scientific papers and is named inventor on numerous multidisciplinary patents. She currently holds non-executive director Board positions on two other high growth healthcare companies.お知らせ • Jun 304Basebio plc Announces Hansjörg Plaggemars, Non-Executive Director, Step Down from the Board4basebio PLC announced that Hansjörg Plaggemars, a non-executive director, requested to step down from the board due to other business commitments which the board has accepted with immediate effect. The board would like to thank Mr. Plaggemars for his contribution to the Company.お知らせ • Jun 084basebio PLC, Annual General Meeting, Jun 28, 20244basebio PLC, Annual General Meeting, Jun 28, 2024.New Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£492k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£7.7m free cash flow). Negative equity (-UK£492k). Earnings have declined by 45% per year over the past 5 years. Revenue is less than US$1m (UK£506k revenue, or US$647k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£7.7m net loss next year). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).Reported Earnings • Jun 06Full year 2023 earnings releasedFull year 2023 results: Net loss: UK£7.67m (loss widened 49% from FY 2022).New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m (UK£354k revenue, or US$447k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£7.7m net loss next year). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.5m free cash flow). Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m (UK£354k revenue, or US$446k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£7.7m net loss next year). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).Reported Earnings • Sep 25First half 2023 earnings released: UK£0.29 loss per share (vs UK£0.20 loss in 1H 2022)First half 2023 results: UK£0.29 loss per share (further deteriorated from UK£0.20 loss in 1H 2022). Net loss: UK£3.56m (loss widened 46% from 1H 2022). Revenue is forecast to grow 121% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom.お知らせ • Aug 014basebio PLC Receives A Grant from the Bill & Melinda Gates Foundation to Advance the Development Program of Thermostable Nucleic Acid Based Vaccines4basebio PLC announced it has received a grant from the Bill & Melinda Gates Foundation to advance the development program of thermostable nucleic acid based vaccines. The development program aims to build on preclinical data demonstrating the improved stability offered by the Hermes™ platform, the superior immune responses achieved with 4basebio's synthetic DNA products and high-quality mRNA produced from 4basebio opDNA™ products. The successful demonstration of the Hermes™ platform and 4basebio synthetic nucleic acid payloads in infectious disease vaccines has the potential to enhance the global availability of such innovative medicines.お知らせ • May 124basebio PLC, Annual General Meeting, Jun 14, 20234basebio PLC, Annual General Meeting, Jun 14, 2023, at 08:00 Coordinated Universal Time.Reported Earnings • May 12Full year 2022 earnings: EPS in line with expectations, revenues disappointFull year 2022 results: UK£0.42 loss per share (further deteriorated from UK£0.26 loss in FY 2021). Net loss: UK£5.15m (loss widened 59% from FY 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) were mostly in line with analyst estimates.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 30First half 2022 earnings released: UK£0.20 loss per share (vs UK£0.13 loss in 1H 2021)First half 2022 results: UK£0.20 loss per share (further deteriorated from UK£0.13 loss in 1H 2021). Net loss: UK£2.43m (loss widened 47% from 1H 2021).Reported Earnings • May 10Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: UK£0.26 loss per share (down from UK£0.078 loss in FY 2020). Net loss: UK£3.24m (loss widened 350% from FY 2020). Revenue exceeded analyst estimates by 69%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Over the next year, revenue is expected to shrink by 11% compared to a 12% growth forecast for the pharmaceuticals industry in the United Kingdom.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.決済の安定と成長配当データの取得安定した配当: 4BBの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 4BBの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場4basebio 配当利回り対市場4BB 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (4BB)n/a市場下位25% (GB)2.2%市場トップ25% (GB)5.6%業界平均 (Biotechs)2.2%アナリスト予想 (4BB) (最長3年)n/a注目すべき配当: 4BBは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 4BBは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 4BBの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 4BBが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YGB 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 04:21終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋4basebio PLC 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Pierre Sylvain RousseauBarclaysAdam McCarterCavendishCharles WestonRBC Capital Markets
お知らせ • 4h4basebio PLC, Annual General Meeting, Jun 30, 20264basebio PLC, Annual General Meeting, Jun 30, 2026. Location: the offices of 4basebio plc, United Kingdom
Reported Earnings • 10hFull year 2025 earnings released: UK£1.09 loss per share (vs UK£0.94 loss in FY 2024)Full year 2025 results: UK£1.09 loss per share (further deteriorated from UK£0.94 loss in FY 2024). Net loss: UK£16.9m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • May 15+ 1 more update4basebio PLC Appoints Richard Bungay as Chief Financial Officer, with Effect from July 20264basebio PLC announced appointment of Richard Bungay as Chief Financial Officer, with effect from July 2026. Richard takes over the role from David Roth, who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period. Richard is an accomplished leader with over 30 years’ senior finance and strategic experience within the pharmaceutical and biotechnology sector, leading both public and private companies from research through all clinical phases, regulatory approval and commercialisation. He joins 4basebio from Sitala Bio Limited, a UK-based private biotech where he helped lead a strategic repositioning of the business, working closely with the CEO and board to raise a signficant Series A round and execute an in-licencing deal with Fosun Pharma for up to $670 million. Richard’s prior roles include CEO and CFO at Diurnal Group plc, where he led its acquisition by Neurocrine Biosciences Inc. in 2022 at a 147% one-day premium, CEO and CFO at Mereo Biopharma Group plc, where he helped in-license a portfolio from Novartis and subsequently completed its AIM IPO, and CFO at Verona Pharma (then listed on the London Stock Exchange, now a subsidiary of Merck & Co) where he helped recapitalise the company. Earlier in his career Richard was the Director of Corporate Communications and Strategic Planning at Celltech Group plc, a London-listed FTSE-100/250 company where he helped execute its acquisition by UCB for £1.5bn. Richard is currently a Non-executive Director of Chroma Therapeutics Ltd. He qualified as a Chartered Accountant with Deloitte and has a First Class degree in Chemistry from Nottingham University.
お知らせ • May 124basebio PLC Launches Enzymatic ssDNA Platform4basebio PLC announced the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines. Built on a proprietary enzymatic manufacturing process, the platform provides biopharma with high-purity, long-form ends protected ssDNA templates, designed to overcome critical manufacturing and performance bottlenecks associated with traditional chemical synthesis in CRISPR-based gene editing, enabling large-scale, clinically viable therapeutics. With the growth of gene editing and with a particular need for complex "knock-in" applications, the demand for longer, purer and safer DNA templates has increased exponentially. 4basebio’s ssDNA offering enables the production of constructs up to 10,000 nucleotides with protected ends, ensuring stability, reduced immunogenicity and a cleaner path to clinical manufacturing. The technical advantages of the platform will be showcased at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston, MA. Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, will deliver a presentation titled "An enzymatic ssDNA platform addresses manufacturing and performance bottlenecks in non-viral CRISPR gene editing" on 14 May at 9:00 AM EDT. At ASGCT, I look forward to presenting data that demonstrates how our long-form ssDNA constructs significantly enhance Homology Directed Repair (HDR) gene editing efficiency while maintaining superior cell viability in sensitive primary cell types. This technology is the bridge between discovery-phase editing and large-scale clinical success. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.
New Risk • May 07New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£71.2m (US$96.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£71.2m market cap, or US$96.6m).
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m).
New Risk • Mar 24New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: UK£74.0m (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (UK£74.0m market cap, or US$99.0m).
お知らせ • Mar 034basebio PLC Promotes Christine Wolosin to Chief Commercial Officer4basebio PLC announced the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice President, Business Development, will lead the Company's global commercial strategy, business development initiatives, and customer engagement as the Company scales its innovative synthetic DNA platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine markets.Christine’s promotion follows the appointment of Dr Amy Walker as Chief Executive Officer, replacing Dr Heikki Lanckriet. Christine will work closely with Amy to execute 4basebio’s accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers seek alternatives to plasmid DNA. Christine brings more than 25 years of experience in the life sciences industry, with a proven track record of building and scaling go-to-market capabilities in the cell and gene therapy space. Prior to joining 4basebio, she served as Vice President of Business Development at Emmes, where she led the buildout of the North America commercial organisation to support growth in biopharma innovator trials and later-phase studies. She established scalable, globally aligned commercial processes and advanced Emmes’ strategic positioning within the biopharma sector. Christine has also held senior global commercial leadership roles at leading life sciences organizations including TriLink BioTechnologies and Thermo Fisher Scientific, where she led the go-to-market launches for a number of advanced therapy offerings, including Thermo Fisher Scientific’s viral vector manufacturing expansion at its flagship Plainville, Massachusetts facility.
お知らせ • Feb 104basebio PLC Announces CEO Changes4basebio PLC announced that Dr Amy Walker has been appointed as Chief Executive Officer, succeeding Dr Heikki Lanckriet, Founder of the Company. After six years in the role, Heikki has stepped down as CEO in order to lead a newly formed entity which will be focussed on advancing the Hermes nanoparticle platform into the clinic. The Board and Executive Leadership team determined that Amy, with her deep knowledge of the company and commercially-focussed skillset and experience, is the right candidate to succeed Heikki as the Company prepares for accelerated commercial growth. Heikki will remain on the Board and will also continue to support the Company’s scientific and technical leadership. David Roth will join Heikki in the newly formed entity and will step down as Chief Financial Officer and as a Director, following an orderly handover period. Amy has been with the Company for more than five years most recently serving as Chief Operating Officer. She has played a key role in scaling 4basebio’s GMP manufacturing capabilities, strengthening direct engagement with top-tier biopharma customers and supporting the Company’s growth operationally and strategically. As Chief Executive Officer, Amy will lead an accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers increasingly seek alternatives to plasmid DNA, and building on the Company’s recent GMP milestone to support clinical programmes in cell and gene therapy and vaccine development. Since the Company’s formation in 2020, Heikki has been responsible for leading 4basebio as it scaled its synthetic DNA technology from concept to clinic, built a global customer base and stewarded 4basebio in building its high-quality investor base.
Reported Earnings • Oct 01First half 2025 earnings released: UK£0.50 loss per share (vs UK£0.45 loss in 1H 2024)First half 2025 results: UK£0.50 loss per share (further deteriorated from UK£0.45 loss in 1H 2024). Net loss: UK£7.80m (loss widened 36% from 1H 2024). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
New Risk • Jun 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£18m net loss next year). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£933k revenue, or US$1.3m).
Reported Earnings • Jun 02Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: UK£0.94 loss per share (further deteriorated from UK£0.62 loss in FY 2023). Net loss: UK£12.3m (loss widened 61% from FY 2023). Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates by 5.0%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
New Risk • May 30New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 41% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.2m). Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Revenue is less than US$1m (UK£596k revenue, or US$803k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£15m net loss next year).
お知らせ • May 284basebio PLC, Annual General Meeting, Jun 27, 20254basebio PLC, Annual General Meeting, Jun 27, 2025.
New Risk • Apr 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.2m). Revenue is less than US$1m (UK£596k revenue, or US$789k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (UK£12m net loss in 3 years).
お知らせ • Apr 024basebio Receives GMP Licence for its UK DNA Manufacturing Facility4basebio PLC announced that it has received Good Manufacturing Practice (GMP) certification from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its UK DNA manufacturing facility. The GMP certification (MIA) granted by the MHRA authorises 4basebio to manufacture and supply both Investigational Medicinal Product (IMP) Drug Substance (Active Pharmaceutical Ingredient; API) and Critical Starting Biological Medicinal materials used in Advanced Therapy Medicinal Products (ATMPs) from its state-of-the-art manufacturing facility in Cambridge. The grant of the GMP certification marks a significant achievement for the Company, proving its ability to produce high-quality, advanced synthetic DNA that meets regulatory standards for clinical applications. The certification both strengthens the Company’s position in the field of advanced therapeutics and progresses the Company towards future product commercialisation and patient care for a range of advanced therapies.
お知らせ • Jan 084basebio PLC Appoints Gabe Longoria as Chief Commercial Officer4basebio PLC announced the appointment of Mr. Gabe Longoria as Chief Commercial Officer (“CCO”) of the Company. The appointment follows the completion of the £40 million investment announced on 12 November 2024, which marked a key milestone in the Company’s journey to deliver scalable, high-quality synthetic DNA solutions to the global market, addressing critical needs in the gene therapy and mRNA vaccine sectors. Gabe’s expertise in scaling commercial operations will play a crucial role in ensuring the Company’s synthetic DNA products reach their full market potential and the Company is well-positioned to deliver on its growth and commercialisation goals in 2025 and beyond. Gabe joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations Ltd. (“Astrea”). During his leadership, the company achieved exceptional financial growth, doubling revenues over a three-year period and expanding its market share globally. His strategic approach to scaling operations and fostering key partnerships solidified Astrea’s position as a leader in biopharmaceutical manufacturing solutions. Gabe has over two decades of commercial leadership in the life sciences sector and expertise in driving revenue growth, market expansion, and strategic partnerships for companies.
お知らせ • Dec 174basebio PLC Announces Appointment of Alan Malus as Independent Non-Executive Director4basebio PLC announced the appointment of Alan Malus as Independent Non-executive Director of the Company, as of 16 December 2024. Mr. Malus has over 18 years of experience in life sciences and diagnostics, having most recently served as Corporate Executive Vice President and President of the Laboratory Products and Services Segment at Thermo Fisher Scientific. He joined Thermo Fisher in 1998, holding numerous executive positions including President Analytical Technologies Group, President Lab Products Group, and President Customer Chanels Group. Prior to this, Mr. Malus spent nearly 15 years in the automotive industry, working with Ford, Chrysler, and Textron Inc., where he served as Vice President of Finance. Since 2023, Mr. Malus has been a Director at Industrial Physics Inc. He also serves as Director at Azenta Life Sciences. Previously, he served as a Director at PHC Holdings Corporation in Japan (2021 to 2022). Mr. Malus graduated from the University of Michigan in 1981, starting his career as a financial analyst at Ford in 1984 and moving to Chrysler in 1986. Current Directorships: USAJapan; Azenta Inc.; Industrial Physics Inc. Previous Directorships held in the past five years: PHC Holdings Corporation.
Recent Insider Transactions • Dec 02Key Executive recently bought UK£158k worth of stockOn the 28th of November, Heikki Lanckriet bought around 12k shares on-market at roughly UK£13.15 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£1.2m. Heikki has been a buyer over the last 12 months, purchasing a net total of UK£158k worth in shares.
お知らせ • Nov 134basebio PLC has completed a Follow-on Equity Offering in the amount of £40.000005 million.4basebio PLC has completed a Follow-on Equity Offering in the amount of £40.000005 million. Security Name: Common Shares Security Type: Common Stock Securities Offered: 2,666,667 Price\Range: £15 Transaction Features: Subsequent Direct Listing
Reported Earnings • Oct 01First half 2024 earnings released: UK£0.45 loss per share (vs UK£0.29 loss in 1H 2023)First half 2024 results: UK£0.45 loss per share (further deteriorated from UK£0.29 loss in 1H 2023). Net loss: UK£5.73m (loss widened 61% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
お知らせ • Aug 094Basebio plc Announces Formation of Strategic Advisory Board and Board Appointment4basebio PLC announced the formation of a Strategic Advisory Board and the appointment of Dr. Amy Walker, the Vice President of Research and Business Development to the Board of Directors of the Company as Chief Operating Officer. Strategic Advisory Board Effective from 1 July 2024, the Company formed a Strategic Advisory Board (“SAB”), with the purpose of offering the Company’s leadership team valuable advice and industry insight spanning technical, operational, commercial and strategic matters as well as supporting the Company in the realisation of its growth goals and objectives. The SAB advisers are engaged for an initial period of 12 months from its formation and will meet with the leadership team periodically. The SAB comprises the following experts: Bertrand Coissac, CEO at Twogene: Mr. Coissac has extensive experience in the life science industry with a focus on cell and gene therapy manufacturing. Before co-founding and leading Twogene, Mr. Coissac was Vice President of Corporate Development at Polyplus which was successfully acquired by Sartorius in July 2023. Lawrence Pitcher, VP at Catalent Pharma Solutions: Mr. Pitcher is currently the Vice President and General Manager, Maryland Gene Therapy Sites at Catalent Pharma Solutions. He brings significant operational and business experience from his current Catalent role and previous roles at Thermo Fisher Scientific where he was most recently the General Manager of the Advance Therapies business. Deborah Barbara, Former Vice President at Maravai Life Sciences: Ms. Barbara has over 30 years of life science industry experience in a variety of strategic business and corporate development roles, most recently as Vice President of Strategy and Corporate Development for Maravai Life Sciences. Prior to joining Maravai, Ms. Barbara was General Manager of Nucleic Acid Therapeutics business for Thermo Fisher Scientific. Appointment of Director: In addition to the above, the Company announces the appointment of Dr. Amy Walker as Chief Operating Officer of the Company. Dr. Walker joined 4basebio in November 2020 and has served as the Vice President of Research and Business Development at the Company. Dr. Walker has a background in molecular biology and gene editing technologies, along with associated nucleic acid nanoparticle delivery platforms. She holds a PhD from UCL Institute of Child Health and was awarded the prestigious Bogue Fellowship, conducting part of her doctoral studies at both University of British Colombia and McGill University, Montreal. Dr. Walker has many years scientific and commercial experience in life sciences, has published scientific papers and is named inventor on numerous multidisciplinary patents. She currently holds non-executive director Board positions on two other high growth healthcare companies.
お知らせ • Jun 304Basebio plc Announces Hansjörg Plaggemars, Non-Executive Director, Step Down from the Board4basebio PLC announced that Hansjörg Plaggemars, a non-executive director, requested to step down from the board due to other business commitments which the board has accepted with immediate effect. The board would like to thank Mr. Plaggemars for his contribution to the Company.
お知らせ • Jun 084basebio PLC, Annual General Meeting, Jun 28, 20244basebio PLC, Annual General Meeting, Jun 28, 2024.
New Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£492k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£7.7m free cash flow). Negative equity (-UK£492k). Earnings have declined by 45% per year over the past 5 years. Revenue is less than US$1m (UK£506k revenue, or US$647k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£7.7m net loss next year). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
Reported Earnings • Jun 06Full year 2023 earnings releasedFull year 2023 results: Net loss: UK£7.67m (loss widened 49% from FY 2022).
New Risk • Apr 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m (UK£354k revenue, or US$447k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£7.7m net loss next year). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£6.5m free cash flow). Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m (UK£354k revenue, or US$446k). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£7.7m net loss next year). Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
Reported Earnings • Sep 25First half 2023 earnings released: UK£0.29 loss per share (vs UK£0.20 loss in 1H 2022)First half 2023 results: UK£0.29 loss per share (further deteriorated from UK£0.20 loss in 1H 2022). Net loss: UK£3.56m (loss widened 46% from 1H 2022). Revenue is forecast to grow 121% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom.
お知らせ • Aug 014basebio PLC Receives A Grant from the Bill & Melinda Gates Foundation to Advance the Development Program of Thermostable Nucleic Acid Based Vaccines4basebio PLC announced it has received a grant from the Bill & Melinda Gates Foundation to advance the development program of thermostable nucleic acid based vaccines. The development program aims to build on preclinical data demonstrating the improved stability offered by the Hermes™ platform, the superior immune responses achieved with 4basebio's synthetic DNA products and high-quality mRNA produced from 4basebio opDNA™ products. The successful demonstration of the Hermes™ platform and 4basebio synthetic nucleic acid payloads in infectious disease vaccines has the potential to enhance the global availability of such innovative medicines.
お知らせ • May 124basebio PLC, Annual General Meeting, Jun 14, 20234basebio PLC, Annual General Meeting, Jun 14, 2023, at 08:00 Coordinated Universal Time.
Reported Earnings • May 12Full year 2022 earnings: EPS in line with expectations, revenues disappointFull year 2022 results: UK£0.42 loss per share (further deteriorated from UK£0.26 loss in FY 2021). Net loss: UK£5.15m (loss widened 59% from FY 2021). Revenue missed analyst estimates by 11%. Earnings per share (EPS) were mostly in line with analyst estimates.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 30First half 2022 earnings released: UK£0.20 loss per share (vs UK£0.13 loss in 1H 2021)First half 2022 results: UK£0.20 loss per share (further deteriorated from UK£0.13 loss in 1H 2021). Net loss: UK£2.43m (loss widened 47% from 1H 2021).
Reported Earnings • May 10Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: UK£0.26 loss per share (down from UK£0.078 loss in FY 2020). Net loss: UK£3.24m (loss widened 350% from FY 2020). Revenue exceeded analyst estimates by 69%. Earnings per share (EPS) also surpassed analyst estimates by 1.5%. Over the next year, revenue is expected to shrink by 11% compared to a 12% growth forecast for the pharmaceuticals industry in the United Kingdom.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.